TGFB1 and pulmonary fibrosis: Its potential mechanisms of action have been identified through network pharmacology predictions, including inhibition of the TGF-β/Smad3 pathway to inhibit TGF-β1-induced AT2 cell proliferation, and inhibition of EMT to alleviate pulmonary fibrosis [75,76].